Backgrounds and Objective Angiopoietin-2(Ang-2)is a promising biomarker and therapeutic target for gastrointestinal angiodysplasia(GIAD).We hypothesized that the lncRNA-HIF1A-AS2/miR-153-3p/HIF-1α/Ang-2 axis plays a ...Backgrounds and Objective Angiopoietin-2(Ang-2)is a promising biomarker and therapeutic target for gastrointestinal angiodysplasia(GIAD).We hypothesized that the lncRNA-HIF1A-AS2/miR-153-3p/HIF-1α/Ang-2 axis plays a critical role in small bowel angiodysplasia(SBAD)-associated angiogenesis,which can be blocked by rifaximin.The purpose of this study was to investigate the expression and pro-angiogenic effects of the lncRNA-HIF1A-AS2/miR-153-3p/HIF-1α/Ang-2 in SBAD and to evaluate the therapeutic potential of rifaximin on SBAD by targeting this axis.Methods The expression and pro-angiogenic effects of lncRNA-HIF1A-AS2/miR-153-3p/HIF-1α/Ang-2 were analysed in SBAD tissues and human umbilical vein endothelial cells(HUVECs).The anti-angiogenic effect of rifaximin and its impact on the lncRNA-HIF1A-AS2/miR-153-3p/HIF-1α/Ang-2 axis were evaluated in HUVECs.Results Increased expression of lncRNA-HIF1A-AS2 and decreased expression of miR-153-3p were detected in SBAD tissues.LncRNA-HIF1A-AS2/miR-153-3p/HIF-1αwere upstream regulators of Ang-2,and this axis was involved in angiogenesis in HUVECs.Rifaximin exerted antiangiogenic effects on HUVECs by blocking this axis.Conclusions The lncRNA-HIF1A-AS2/miR-153-3p/HIF-1α/Ang-2 axis is critically involved in SBAD-associated angiogenesis.Rifaximin is a potential therapeutic option for SBAD via blockade of this axis.展开更多
基金supported by the Hubei Province Natural ScienceFoundation(No.2022CFC010).
文摘Backgrounds and Objective Angiopoietin-2(Ang-2)is a promising biomarker and therapeutic target for gastrointestinal angiodysplasia(GIAD).We hypothesized that the lncRNA-HIF1A-AS2/miR-153-3p/HIF-1α/Ang-2 axis plays a critical role in small bowel angiodysplasia(SBAD)-associated angiogenesis,which can be blocked by rifaximin.The purpose of this study was to investigate the expression and pro-angiogenic effects of the lncRNA-HIF1A-AS2/miR-153-3p/HIF-1α/Ang-2 in SBAD and to evaluate the therapeutic potential of rifaximin on SBAD by targeting this axis.Methods The expression and pro-angiogenic effects of lncRNA-HIF1A-AS2/miR-153-3p/HIF-1α/Ang-2 were analysed in SBAD tissues and human umbilical vein endothelial cells(HUVECs).The anti-angiogenic effect of rifaximin and its impact on the lncRNA-HIF1A-AS2/miR-153-3p/HIF-1α/Ang-2 axis were evaluated in HUVECs.Results Increased expression of lncRNA-HIF1A-AS2 and decreased expression of miR-153-3p were detected in SBAD tissues.LncRNA-HIF1A-AS2/miR-153-3p/HIF-1αwere upstream regulators of Ang-2,and this axis was involved in angiogenesis in HUVECs.Rifaximin exerted antiangiogenic effects on HUVECs by blocking this axis.Conclusions The lncRNA-HIF1A-AS2/miR-153-3p/HIF-1α/Ang-2 axis is critically involved in SBAD-associated angiogenesis.Rifaximin is a potential therapeutic option for SBAD via blockade of this axis.
